Carol Gallagher has had a 35 year career in the biopharmaceutical industry serving in operating roles, venture capital investment, and as a board director in both public and private companies.  Public companies where she has been a director or is currently a director include AnaptysBio, Annexon, Atara Bio, Frazier Life Sciences Acquisition Company, Metacrine, Millendo Therapeutics, Mirati, PMV Pharmaceuticals, and Turning Point Therapeutics.

She served as a biopharma investor starting as a Venture Partner at Frazier Healthcare from 2013-2014.  From 2014-2023, she was a Partner and then Advisor at New Enterprise Associates where she led investments in early-stage biopharma companies.  Through her investing and board work, she has been involved in multiple M&A exits and in guiding companies through successful IPOs as well the development of three recently approved therapies.

From 1989-2011, Dr. Gallagher enjoyed a successful and varied operating career in both large and small biopharmaceutical companies.  She started her career in sales and marketing at Eli Lilly and held various positions of increasing responsibility in commercial, drug development and business development at companies such as Amgen, Agouron Pharmaceuticals, Pfizer, IDEC Pharmaceuticals (where she led the RITUXAN  team), CancerVax, Anadys, and Metastatix.  Starting in 2008, Dr. Gallagher was President and CEO of Calistoga Pharmaceuticals which developed ZYDELIG and was acquired by Gilead in 2011.

Dr. Gallagher studied chemistry at Vanderbilt University and received BS and Doctor of Pharmacy degrees from the University of Kentucky College of Pharmacy in 1989.

Anna originally started her career as a Social Worker with the Department of Children & Families in Connecticut, after achieving her degree in this field from the University of New Hampshire. Anna then decided to move out of this field and transitioned into an Executive Assistant role with Gritstone Bio, taking on a range of tasks including office administration and events management, as well as getting involved with HR related tasks.

Donata is an Assistant Accountant at Apollo. Prior to joining Apollo, Donata held various finance roles at companies such as Darktrace Limited and DisplayLink providing support for senior finance team members.  

Dr Dipender Gill is an accomplished leader in leveraging human-centric evidence to inform drug discovery and development. Having achieved a Distinction in his undergraduate medical training at the University of Oxford, Dipender worked for more than 10 years as a Clinician Scientist at Imperial College London and its affiliated hospitals, where he received his PhD, published more than 250 research papers, and completed postgraduate clinical training in General Internal Medicine and Clinical Pharmacology.

Dipender went on to work for more than 3 years at Novo Nordisk, where he was responsible for optimizing incorporation of human-centric evidence across the portfolio. In this role, Dipender generated evidence to help develop the GLP1, IL6, FGF21 and CNP programs. On leaving Novo Nordisk as the highest valued company in Europe in 2023, he was ranked as the most prolific employee for academic output in the whole organization.

As current CEO of Sequoia Genetics, a London-based consultancy specializing in leveraging human genetic data to generate translational insights, Dipender works with investors, biotech and pharma on maximizing the efficiency of drug discovery and development efforts.

Previously, Laurie worked at Sanofi and Kadmon Pharmaceuticals where she was an integral team member of a pivotal trial that achieved NDA approval.  Laurie has a Masters degree in Education and a Bachelor of Science degree in Biomedical Engineering.   

Mel is a Program Director at Apollo Therapeutics specialising in chemical biology, IP and drug substance CMC. Before joining Apollo, Mel was involved in several successful biotech companies, latterly as Head of Chemistry at Centauri Therapeutics. Prior to that, Mel spent 17 years in Discovery Chemistry at Pfizer. Mel is a fellow of the Royal Society of Chemistry, a Chartered Chemist, and obtained her degree in chemistry at the University of Southampton. 

Rachel has more than 25 years experience in research and development with expertise at the laboratory bench, in the clinic, and program leadership. Before joining Apollo Therapeutics, Rachel held roles at Merck, Sharpe and Dohme, Pfizer, Cerevel Therapeutics and Noema Pharma. She obtained a bachelors degree in Medicine and Pharmacology from the University of Sheffield, and a post-doctorate in Translational Pharmacology from Kingston University. 

Jordyn has a masters degree in Regulatory Affairs, specializing in Clinical Operations. She has been involved in clinical research for over 8 years, working in hospital clinics as well as within industry, and has experience across multiple therapeutic areas and phases of clinical trials.

Jamie Heath is Apollo Therapeutics’ Chief Financial Officer. He has over 25 years of experience in corporate finance based in London and New York, specializing in working with global life science companies. Recently, he served as Chief Development Officer at BTG Plc with responsibility for corporate strategy and business development. In this role, he oversaw a number of acquisitions, in-licensing deals and joint ventures, including the sale of the company to Boston Scientific for $4 billion. Jamie has led numerous M&A and capital raising transactions and held senior roles at Merrill Lynch, Centerview Partners and Deutsche Bank. He holds a master’s degree from Oxford University. 

Juan is a Fellow Chartered Certified Accountant. Before joining Apollo, he spent six years in various finance roles at AstraZeneca. Prior to that, he worked across a mixture of public and limited companies in Cambridge, UK.

Steph is a VP and Program Director at Apollo Therapeutics. Prior to joining Apollo, Steph worked at GlaxoSmithKline in the Biopharmaceuticals division for 13 years leading technology and therapeutics pre-clinical programs, with a track record of successful transition of several programs to the clinic.  She then left pharma to join Tusk Therapeutics (acquired by Roche in 2015) as a Principal Scientist working on translational biology. Steph joined Apollo Therapeutics five years ago and leads multiple programs, using her experience to drive the progression of cutting-edge science into translational drug discovery and development programs.

Louise is a People Advisor who obtained a BSc in Business Management from the University of East Anglia. She started her career working in a small Biotech company which experienced rapid growth, before moving to a Biopharma company working with teams across both the UK and US. She then moved into HR Consulting where she supported clients across a number of industries and gained exposure to different areas of HR. Louise has since made the move back to Biopharma and continues to support both the UK and US team.